Cargando…
Discovery of 3-Alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as Selective, Orally Bioavailable CHK1 Inhibitors
[Image: see text] Inhibitors of checkpoint kinase 1 (CHK1) are of current interest as potential antitumor agents, but the most advanced inhibitor series reported to date are not orally bioavailable. A novel series of potent and orally bioavailable 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbon...
Autores principales: | Lainchbury, Michael, Matthews, Thomas P., McHardy, Tatiana, Boxall, Kathy J., Walton, Michael I., Eve, Paul D., Hayes, Angela, Valenti, Melanie R., de Haven Brandon, Alexis K., Box, Gary, Aherne, G. Wynne, Reader, John C., Raynaud, Florence I., Eccles, Suzanne A., Garrett, Michelle D., Collins, Ian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2012
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506129/ https://www.ncbi.nlm.nih.gov/pubmed/23082860 http://dx.doi.org/10.1021/jm3012933 |
Ejemplares similares
-
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma
por: Walton, Mike I., et al.
Publicado: (2015) -
Structure-Guided Evolution
of Potent and Selective
CHK1 Inhibitors through Scaffold Morphing
por: Reader, John C., et al.
Publicado: (2011) -
Diaquabis[5-(2-pyrazin-2-yl)tetrazolato]copper(II)–pyrazine-2-carbonitrile (1/2)
por: Bensegueni, Mohamed Abdellatif, et al.
Publicado: (2014) -
2-[(2-Hydroxybenzyl)amino]pyrazinium perchlorate–2-[(pyrazin-2-ylamino)methyl]phenol (1/1)
por: Gao, Shan, et al.
Publicado: (2012) -
Bis[5-(2-pyridyl)pyrazine-2-carbonitrile]silver(I) tetrafluoridoborate
por: Wang, Zi-Jia, et al.
Publicado: (2010)